Hemab Therapeutics

Every step we take at Hemab is driven by a single purpose: reaching the overlooked patients who have been waiting decades for better blood coagulation treatments. Today as we are officially a @Nasdaq-listed company (COAG), it isn't about celebrating a corporate victory, it's about fueling the hard work ahead to bring those much-needed treatments to life. We share this day with the dedicated employees, partners, stakeholders and patient community members working alongside us to make meaningful progress towards treatments. Read more: ir.hemab.com/news-releases/…

Horizon blindness is what happens when patients stop expecting better: a rational response when nothing better has been offered. GT360, VWD360, and FVIID360 – our natural history studies – were designed to ask the questions that have historically gone unasked. The lived experiences reshaped how we think about disease burden: in GT360, 88% of participants had bled in the past week and approximately 30% met criteria for symptomatic depression. And across the board, quality of life was further driven down by anxiety. Patient voices make better therapies possible, and our natural history studies are where it all begins. At Hemab, we’re working toward a future where the horizon feels visible again: #research-approach" target="_blank" rel="nofollow noopener">hemab.com/about-us#resea…

Iron deficiency and iron deficiency anemia disproportionately affect Black women of reproductive age — with prevalence rates up to five times higher than the general female population. They're told their periods are "just heavy." They research and buy iron supplements. They schedule their lives around heavy bleeding episodes that never got diagnosed. When an underserved bleeding disorder presents as a common symptom, it gets normalized. When it's normalized in a community already facing diagnostic delays, our ability to close gaps in health equity disappears entirely. April is National Minority Health Month. This week is Black Maternal Health Week. Both exist because the same women keep falling through the same gaps. And today, World Health Day, is a reminder that bleeding disorders drive global health burdens like iron deficiency and anemia and these remain largely unrecognized. For a healthier world tomorrow, recognizing the overlooked and getting to a diagnosis of bleeding disorders is a critical first step.

Clinicians see patients for minutes. Patients live with their condition for a lifetime. Natural history studies reveal what patients experience every day – beyond the clinic walls and beyond horizon blindness, where patients stop asking for more because they’ve been told nothing exists. Sharing your lived experience helps researchers see the full impact of bleeding disorders and shapes the development of better treatments. VELORA Discover, a screening study of bleeding and treatment in people living with Von Willebrand disease (VWD), has already helped redefine our understanding of Type 1 VWD, and by contributing your story, you can help continue to shape research and care. Learn more and join at hemab.typeform.com/contact

Underserved bleeding disorders are finally in focus, buttreating them still requires looking at the full picture. Factor VII deficiency (FVIID) is a rare, inherited bleeding disorder caused by low levels of factor VII, a protein essential for initiating blood clotting. People living with FVIID experience spontaneous to life-threatening bleeds. But understanding FVIID means looking beyond bleed rates to the lived experiences. The FVIID360 natural history study sheds light on both the clinical experience of bleeding and the psychosocial burden of living with a chronic condition, highlighting under‑use of prophylaxis and the strong social and emotional impact on patients – including pain, limits on activity, lost work or education, and feelings of isolation, even when factor levels appear mild. Throughout Bleeding Disorders Awareness Month, we’re calling attention to both the disease landscape and patients’ lived experience to drive progress for conditions too often overlooked.

Team Hemab had an incredible time at the THSNA Summit in Portland, presenting insights on HMB-002, connecting with the thrombosis and hemostasis community, and learning from the latest research in bleeding and clotting disorders. A highlight of the event was meeting with our Von Willebrand Disease Investigators, where we engaged, exchanged ideas, and strengthened collaborations that advance care for patients. Thank you to everyone who joined us. Together, we’re driving progress in underserved bleeding and clotting disorders.

💬 “I never met someone with Glanzmann thrombasthenia before…” At Hemab, we’re connecting people with Glanzmann thrombasthenia (GT) worldwide by partnering with @sanogenetics on the Global Voices of GT survey. Share your story, meet others who understand, and be the first to hear about future events and initiatives: portal.sanogenetics.com/en-us/study/he…

We’re heading to THSNA 2026! Every milestone in our science starts with a conversation, whether with a lived experience expert, clinician, or a researcher who refuses to accept the status quo in overlooked bleeding disorders. Portland is where those conversations continue. Don’t miss our March 21st oral presentation for the latest on HMB-002, our investigational backbone therapy for the prophylactic treatment of Von Willebrand disease (VWD). Interested in meeting about VWD, Glanzmann thrombasthenia, Factor VII deficiency, or other earlier-stage programs? Send a DM or leave a comment below!

💬 "I never met someone with this before.” For many people living with ultra-rare bleeding disorders, that sentence shapes their entire lives. No peer support. No shared vocabulary. No one who already knows what it's like. Hemab is working to change that because the patients who share their stories are the ones who advance the field. Their lived experiences inform our natural history studies, sharpen our research, and remind us of exactly what's at stake. Just as science has meaningfully improved the lives of people living with hemophilia, PKU, and Gaucher disease, we believe it can do the same for every bleeding disorder. On Ultra Rare Bleeding Disorder Day during Bleeding Disorders Awareness Month, we celebrate these voices and the progress they inspire. If you want to share your voice, connect with others, or simply be heard — our team is ready to chat: hemab.com/contact-us

Glanzmann thrombasthenia (GT) has been in medical literature since 1918. For over a century, the story was the same: rare platelet disorder. Severe bleeding. Limited options. What that literature never captured, until now, are the lived experiences of people living with GT. So, we asked. Throughout Bleeding Disorders Awareness Month, we’re highlighting insights from natural history studies, including GT360, which recruited over 100 people with GT across 20 countries to describe their daily lives. The results were stark: 88% had bled in the past week, 30% met criteria for symptomatic depression, and quality of life was driven down not primarily by pain, but by anxiety. At Hemab, we’re listening, innovating, and partnering with the GT community to advance the first prophylactic treatment. Explore the lived experiences of GT at rpthjournal.org/article/S2475-…

Heavy menstrual bleeding (HMB) is one of the most overlooked challenges in women’s health – especially for women living with underserved bleeding disorders. More than 80% of women living with Glanzmann thrombasthenia, Von Willebrand disease, and Factor VII deficiency experience HMB. This International Women’s Day, we recognize this year’s theme, Give to Gain, and the women whose courage is driving progress for generations to come. From participating in clinical trials to advancing research and care, their impact extends far beyond today. At Hemab, we’re committed to improving care for women at every stage of life by addressing silent diseases like HMB and closing long-standing gaps in women’s health. Our women scientists, physicians, and leaders are helping drive that change. 💡 Watch to learn more about the female side of hematology.

Too many people living with Von Willebrand disease (VWD) are still being underestimated and overlooked. Insights from the VWD360 natural history study reveal a much greater unmet need than previously understood, highlighting significant socioeconomic and psychological burdens driven by frequent bleeding, missed work, and impacts on mental well-being. During Bleeding Disorders Awareness Month, we’re sharing these perspectives to help bring focus to a community that has been underserved for too long, reinforcing the need for progress grounded in lived experience.

Today, there is no approved prophylactic treatment for Glanzmann thrombasthenia (GT). Sutacimig is being developed with the goal of changing that. The FDA has granted Breakthrough Therapy Designation for sutacimig based on preliminary clinical evidence that suggest our bispecific antibody demonstrates substantial improvement over the existing standard of care for GT. For a community that has been overlooked and with serious unmet need, this milestone reflects meaningful progress toward a potential treatment option they deserve. Read the full announcement: hemab.com/news-items/hem…

For over a century, medicine looked away. Glanzmann thrombasthenia (GT) was first described in 1918, and for most of the hundred years that followed, patients were left without effective therapies. So, the GT community became resilient. Today, on GT Awareness Day, we pause to honor that. The day-to-day reality of GT: spontaneous bleeds, disrupted lives, procedures deferred. It demands a tenacity that most of us will never fully understand. And yet, this community shows up. To every person living with GT who adapted, endured, and kept going: you are fueling the science. The wait is not over. But, for the first time in a century, the attention is catching up. Follow along during Bleeding Disorders Awareness Month as we share the perspectives, data, and scientific progress shaping the future of overlooked bleeding disorders.

As Rare Disease Day shines a light on overlooked conditions, it also challenges how we think about the word “rare.” More than 300 million people globally live with a rare disease, including those affected by bleeding disorders such as Glanzmann thrombasthenia, Von Willebrand disease, Factor VII deficiency, and other coagulation disorders. One by one these conditions are uncommon. Together, they’re not rare at all. At Hemab, we’re dedicated to advancing understanding of these disorders through research and clinical trials, because participation today can help improve care for countless people tomorrow. As we reflect on Rare Disease Day, we’re also looking ahead to Bleeding Disorders Awareness Month, where we’ll continue sharing the science, the stories, and the progress shaping the future of care.

Patient-centric breakthroughs start with a deep understanding of what it means to live with a disease. One patient is an anecdote. A few patients are an interesting finding. A natural history study with global perspectives? That's where the real patterns emerge. We run these studies not to confirm what we already believe, but to find what's been missed. Stay tuned for a deeper look into our natural history studies during Bleeding Disorders Awareness Month.

From research in the lab to real treatments for patients, every step of drug discovery and development matters. But without clinical trial participation, new medicines can’t move forward. At Hemab, we’re advancing prophylactic therapies that address the root causes of underserved and overlooked bleeding disorders. Each trial phase, from early safety studies to larger efficacy trials, brings new options closer to people who need them. Participation isn’t just enrollment. It’s a chance to shape the future of care. Learn more about our clinical trials at #clinical-trials" target="_blank" rel="nofollow noopener">hemab.com/for-patients-c…